Neurotrophic gene polymorphisms and response to psychological therapy

Translational Psychiatry

Volumn 2, Issue , 2012, Pages

  Lester, K J ^a   Hudson, J L ^b   Tropeano, M ^a   Creswell, C ^c   Collier, D A ^a   Farmer, A ^a   Lyneham, H J ^b   Rapee, R M ^b   Eley, T C ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b MACQUARIE UNIVERSITY   (Australia)

^c UNIVERSITY OF READING   (United Kingdom)

Author keywords

anxiety; CBT; children; genetics; therapeutics; treatment response

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; DNA; NERVE GROWTH FACTOR; SEROTONIN TRANSPORTER; SLC6A4 PROTEIN, HUMAN;

ADOLESCENT; ANXIETY DISORDER; AUSTRALIA; CHEEK; CHILD; CHILDHOOD DISEASE; COGNITION; COGNITIVE THERAPY; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MENTAL STRESS; MOOD; NERVE CELL PLASTICITY; PHENOTYPE; PRESCHOOL CHILD; REVIEW; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; UNITED KINGDOM; ALLELE; ARTICLE; CASE CONTROL STUDY; GENE EXPRESSION; GENETICS; GENOTYPE; PROGNOSIS;

ADOLESCENT; ALLELES; ANXIETY DISORDERS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CASE-CONTROL STUDIES; CHILD; COGNITIVE THERAPY; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; MALE; NERVE GROWTH FACTOR; NEURONAL PLASTICITY; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TREATMENT OUTCOME;

EID: 84860439886     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2012.33     Document Type: Review

References (80)

1. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry 2005; 62: 593-602. (Pubitemid 40973434)
2. Merikangas KR, He JP, Burstein M, Swanson SA, Avenevoli S, Cui L et al. Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication-Adolescent Supplement (NCS-A). J Am Acad Child Adolesc Psychiatry 2010; 49: 980-989.
3. Weems CF. Developmental trajectories of childhood anxiety: identifying continuity and change in anxious emotion. Dev Rev 2008; 28: 488-502.
4. Asendorpf JB, Denissen JJA, van Aken MAG. Inhibited and aggressive preschool children at 23 years of age: Personality and social transitions into adulthood. Dev Psychol 2008; 44: 997-1011.
5. Erath S, Flanagan K, Bierman K. Social anxiety and peer relations in early adolescence: behavioral and cognitive factors. J Abnorm Child Psychol 2007; 35: 405-416. (Pubitemid 46980441)
6. Owens M, Stevenson J, Norgate R, Hadwin J. Processing efficiency theory in children: working memory as a mediator between trait anxiety and academic performance. Anxiety Stress Copin 2008; 21: 417-430.
7. Kim-Cohen J, Caspi A, Moffitt TE, Harrington H, Milne BJ, Poulton R. Prior juvenile diagnoses in adults with mental disorder: developmental follow-back of a prospectivelongitudinal cohort. Arch Gen Psychiatry 2003; 60: 709-717. (Pubitemid 36818633)
8. Beesdo K, Hoyer, Jacobi F, Low NCP, Hfler M, Wittchen H-U. Association between generalized anxiety levels and pain in a community sample: Evidence for diagnostic specificity. J Anxiety Disord 2009; 23: 684-693.
9. James A, Soler A, Weatherall R. Cognitive behavioural therapy for anxiety disorders in children and adolescents. Cochrane Database of Systematic Reviews 2005.
10. Hudson JL. Efficacy of cognitive-behavioural therapy for children and adolescents with anxiety disorders. Behav Change 2005; 22: 55-70. (Pubitemid 41051837)
11. Bodden DH, Bogels SM, Nauta MH, De Haan E, Ringrose J, Appelboom C et al. Child versus family cognitive-behavioral therapy in clinically anxious youth: an efficacy and partial effectiveness study. J Am Acad Child Adolesc Psychiatry 2008; 47: 1384-1394.
12. Rapee RM, Schniering CA, Hudson JL. Anxiety disorders during childhood and adolescence: origins and treatment. Ann Rev Clin Psychol 2009; 5: 311-341.
13. Ollendick TH, Jarrett MA, Grills-Taquechel AE, Hovey LD, Wolff JC. Comorbidity as a predictor and moderator of treatment outcome in youth with anxiety, affective, attention deficit/hyperactivity disorder, and oppositional/conduct disorders. Clin Psychol Rev 2008; 28: 1447-1471.
14. Keers R, Aitchison KJ. Pharmacogenetics of antidepressant response. Expert Rev Neurother 2011; 11: 101-125.
15. Eley TC, Hudson JL, Creswell C, Tropeano M, Lester KJ, Cooper P et al. Therapygenetics: The 5HTTLPR and response to psychological therapy. Mol Psychiatry 2012; 17: 236-237.
16. Fox E, Zougkou K, Ridgewell A, Garner K. The serotonin transporter gene alters sensitivity to attention bias modification: evidence for a plasticity gene. Biol Psychiatry 2011; 70: 1049-1054.
17. Steiger H, Joober R, Gauvin L, Bruce KR, Richardson J, Israel M et al. Serotonin-system polymorphisms (5-HTTLPR and -1438G/A) and responses of patients with bulimic syndromes to multimodal treatments. J Clin Psychiatry 2008; 69: 1565-1571.
18. Lonsdorf TB, Ruck C, Bergstrom J, Andersson G, Ohman A, Lindefors N et al. The COMTval158met polymorphism is associated with symptom relief during exposure-based cognitive-behavioral treatment in panic disorder. BMC Psychiatry 2010; 10: 99.
19. Beevers CG, McGeary JE. Therapygenetics: moving towards personalized psychotherapy treatment. Trends Cogn Sci 2012; 16: 11-12.
20. Cirulli F, Alleva E. The NGF saga: from animal models of psychosocial stress to stressrelated psychopathology. Front Neuroendocrinol 2009; 30: 379-395.
21. Castren E, Voikar V, Rantamaki T. Role of neurotrophic factors in depression. Curr Opin Pharm 2007; 7: 18-21. (Pubitemid 46238033)
22. Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 2008; 64: 527-532.
23. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006; 59: 1116-1127.
24. Syed Z, Dudbridge F, Kent L. An investigation of the neurotrophic factor genes GDNF, NGF, and NT3 in susceptibility to ADHD. Am J Med Genet B 2007; 144B: 375-378. (Pubitemid 46642033)
25. Branchi I, D'Andrea I, Fiore M, Di Fausto V, Aloe L, Alleva E. Early social enrichment shapes social behavior and nerve growth factor and brain-derived neurotrophic factor levels in the adult mouse brain. Biol Psychiatry 2006; 60: 690-696. (Pubitemid 44427759)
26. Cirulli F, Alleva E, Antonelli A, Aloe L. NGF expression in the developing rat brain: effects of maternal separation. Brain Res Dev Brain Res 2000; 123: 129-134.
27. Cirulli F, Francia N, Branchi I, Antonucci MT, Aloe L, Suomi SJ et al. Changes in plasma levels of BDNF and NGF reveal a gender-selective vulnerability to early adversity in rhesus macaques. Psychoneuroendocrinology 2009; 34: 172-180.
28. Alleva E, Santucci D. Psychosocial vs 'physical' stress situations in rodents and humans: role of neurotrophins. Physiol Behav 2001; 73: 313-320. (Pubitemid 32595704)
29. Aloe L, Bracci-Laudiero L, Alleva E, Lambiase A, Micera A, Tirassa P. Emotional stress induced by parachute jumping enhances blood nerve growth factor levels and the distribution of nerve growth factor receptors in lymphocytes. Proc Natl Acad Sci USA 1994; 91: 10440-10444. (Pubitemid 24329013)
30. Jockers-Scherubl MC, Zubraegel D, Baer T, Linden M, Danker-Hopfe H, Schulte-Herbruggen O et al. Nerve growth factor serum concentrations rise after successful cognitive-behavioural therapy of generalized anxiety disorder. Prog NeuroPsychopharmacol Biol Psychiatry 2007; 31: 200-204. (Pubitemid 44970510)
31. Lang UE, Hellweg R, Bajbouj M, Gaus V, Sander T, Gallinat J. Gender-dependent association of a functional NGF polymorphism with anxiety-related personality traits. Pharmacopsychiatry 2008; 41: 196-199.
32. Cui D, Zhang H, Yang BZ, Listman JB, Li D, Price LH et al. Variation in NGFB is associated with primary affective disorders in women. Am J Med Genet B Neuropsychiatr Genet 2011; 156B: 401-412.
33. Mattson MP, Maudsley S, Martin B. BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders. Trends Neurosci 2004; 27: 589-594. (Pubitemid 39221394)
34. Martinowich K, Lu B. Interaction between BDNF and serotonin: role in mood disorders. Neuropsychopharmacology 2008; 33: 73-83. (Pubitemid 350191318)
35. Chen B, Dowlatshahi D, MacQueen GM, Wang J-F, Young LT. Increased hippocampal bdnf immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 2001; 50: 260-265. (Pubitemid 32778442)
36. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003; 112: 257-269. (Pubitemid 36144114)
37. Chen ZY, Jing D, Bath KG, Ieraci A, Khan T, Siao CJ et al. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science 2006; 314: 140-143. (Pubitemid 44547760)
38. Bueller JA, Aftab M, Sen S, Gomez-Hassan D, Burmeister M, Zubieta JK. BDNF Val66Met allele is associated with reduced hippocampal volume in healthy subjects. Biol Psychiatry 2006; 59: 812-815.
39. Frodl T, Schule C, Schmitt G, Born C, Baghai T, Zill P et al. Association of the brain-derived neurotrophic factor Val66Met polymorphism with reduced hippocampal volumes in major depression. Arch Gen Psychiatry 2007; 64: 410-416. (Pubitemid 46556460)
40. Gallinat J, Schubert F, Bruhl R, Hellweg R, Klar AA, Kehrer C et al. Met carriers of BDNF Val66Met genotype show increased N-acetylaspartate concentration in the anterior cingulate cortex. Neuroimage 2010; 49: 767-771.
41. Hariri AR, Goldberg TE, Mattay VS, Kolachana BS, Callicott JH, Egan MF et al. Brainderived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci 2003; 23: 6690-6694. (Pubitemid 36951196)
42. Hajcak G, Castille C, Olvet DM, Dunning JP, Roohi J, Hatchwell E. Genetic variation in brain-derived neurotrophic factor and human fear conditioning. Genes Brain Behav 2009; 8: 80-85.
43. Lang UE, Hellweg R, Kalus P, Bajbouj M, Lenzen KP, Sander T et al. Association of a functional BDNF polymorphism and anxiety-related personality traits. Psychopharmacology (Berl) 2005; 180: 95-99. (Pubitemid 40897075)
44. Sen S, Nesse RM, Stoltenberg SF, Li S, Gleiberman L, Chakravarti A et al. A BDNF coding variant is associated with the neo personality inventory domain neuroticism, a risk factor for depression. Neuropsychopharmacology 2003; 28: 397-401.
45. Frustaci A, Pozzi G, Gianfagna F, Manzoli L, Boccia S. Meta-analysis of the brain-derived neurotrophic factor gene (BDNF) Val66Met polymorphism in anxiety disorders and anxietyrelated personality traits. Neuropsychobiology 2008; 58: 163-170.
46. Willis-Owen SA, Fullerton J, Surtees PG, Wainwright NW, Miller S, Flint J. The Val66Met coding variant of the brain-derived neurotrophic factor (BDNF) gene does not contribute toward variation in the personality trait neuroticism. Biol Psychiatry 2005; 58: 738-742. (Pubitemid 41547242)
47. Terracciano A, Sanna S, Uda M, Deiana B, Usala G, Busonero F et al. Genome-wide association scan for five major dimensions of personality. Mol Psychiatry 2010; 15: 647-656.
48. van den Oord EJCG, Kuo P-H, Hartmann AM, Webb BT, Moller H-J, Hettema JM et al. Genomewide association analysis followed by a replication study implicates a novel candidate gene for neuroticism. Arch Gen Psychiatry 2008; 65: 1062-1071.
49. Terracciano A, Tanaka T, Sutin AR, Deiana B, Balaci L, Sanna S et al. BDNF Val66Met is associated with introversion and interacts with 5-HTTLPR to influence neuroticism. Neuropsychopharmacology 2010; 35: 1083-1089.
50. Montag C, Basten U, Stelzel C, Fiebach CJ, Reuter M. The BDNF Val66Met polymorphism and anxiety: Support for animal knock-in studies from a genetic association study in humans. Psychiatry Res 2010; 179: 86-90.
51. Gatt JM, Nemeroff CB, Dobson-Stone C, Paul RH, Bryant RA, Schofield PR et al. Interactions between BDNF Val66Met polymorphism and early life stress predict brain and arousal pathways to syndromal depression and anxiety. Mol Psychiatry 2009; 14: 681-695.
52. Dougherty LR, Klein DN, Congdon E, Canli T, Hayden EP. Interaction between 5-HTTLPR and BDNF Val66Met polymorphisms on HPA axis reactivity in preschoolers. Biol Psychol 2010; 83: 93-100.
53. Pezawas L, Meyer-Lindenberg A, Goldman AL, Verchinski BA, Chen G, Kolachana BS et al. Evidence of biologic epistasis between BDNF and SLC6A4 and implications for depression. Mol Psychiatry 2008; 13: 709-716. (Pubitemid 351861533)
54. Hunnerkopf R, Strobel A, Gutknecht L, Brocke B, Lesch KP. Interaction between BDNF Val66Met and dopamine transporter gene variation influences anxiety-related traits. Neuropsychopharmacology 2007; 32: 2552-2560. (Pubitemid 350126836)
55. Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 2010; 15: 473-500.
56. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association: Washington, DC, 1994.
57. Lyneham HJ, Schniering CA, Hudson JL, Rapee RM. The Cool Kids Program - Adolescent Version. Macquarie University Anxiety Research Unit: Sydney, 2005.
58. Schosser A, Gaysina D, Cohen-Woods S, Chow PC, Martucci L, Craddock N et al. Association of DISC1 and TSNAX genes and affective disorders in the depression casecontrol (DeCC) and bipolar affective case-control (BACCS) studies. Mol Psychiatry 2010; 15: 844-849.
59. Silverman WK, Albano AM. The Anxiety Disorders Interview Schedule for Children-IV (Child and Parent Versions). Oxford University Press: New York, 1996.
60. Hudson JL, Rapee RM, Deveney C, Schniering CA, Lyneham HJ, Bovopoulos N. Cognitive-behavioral treatment versus an active control for children and adolescents with anxiety disorders: a randomized trial. J Am Acad Child Adolesc Psychiatry 2009; 48: 533-544.
61. Lyneham HJ, Abbott MJ, Rapee RM. Interrater reliability of the anxiety disorders interview schedule for dsm-iv: child and parent version. J Am Acad Child Adolesc Psychiatry 2007; 46: 731-736. (Pubitemid 46816826)
62. Lovibond PF, Lovibond SH. The structure of negative emotional states: comparison of the depression anxiety stress scales (dass) with the beck depression and anxiety inventories. Behav Res Ther 1995; 33: 335-343.
63. Freeman B, Powell J, Ball D, Hill L, Craig I, Plomin R. DNA by mail: an inexpensive and noninvasive method for collecting DNA samples from widely dispersed populations. Behav Genet 1997; 27: 251-257.
64. Freeman B, Smith N, Curtis C, Huckett L, Mill J, Craig IW. DNA from buccal swabs recruited by mail: evaluation of storage effects on long-term stability and suitability for multiplex polymerase chain reaction genotyping. Behav Genet 2003; 33: 67-72. (Pubitemid 36176783)
65. Mossner R, Daniel S, Albert D, Heils A, Okladnova O, Schmitt A et al. Serotonin transporter function is modulated by brain-derived neurotrophic factor (BDNF) but not nerve growth factor (NGF). Neurochem Int 2000; 36: 197-202. (Pubitemid 30047011)
66. Garland EL, Howard MO. Neuroplasticity, psychosocial genomics, and the biopsychosocial paradigm in the 21st century. Health Soc Work 2009; 34: 191-199.
67. Frewen PA, Dozois DJ, Lanius RA. Neuroimaging studies of psychological interventions for mood and anxiety disorders: empirical and methodological review. Clin Psychol Rev 2008; 28: 228-246.
68. Goldapple K, Segal Z, Garson C, Lau M, Bieling P, Kennedy S et al. Modulation of corticallimbic pathways in major depression: treatment-specific effects of cognitive behavior therapy. Arch Gen Psychiatry 2004; 61: 34-41. (Pubitemid 38044639)
69. Martin SD, Martin E, Rai SS, Richardson MA, Royall R. Brain blood flow changes in depressed patients treated with interpersonal psychotherapy or venlafaxine hydrochloride: preliminary findings. Arch Gen Psychiatry 2001; 58: 641-648. (Pubitemid 32640858)
70. Baxter Jr LR, Schwartz JM, Bergman KS, Szuba MP, Guze BH, Mazziotta JC et al. Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Arch Gen Psychiatry 1992; 49: 681-689.
71. Nakatani E, Nakgawa A, Ohara Y, Goto S, Uozumi N, Iwakiri M et al. Effects of behavior therapy on regional cerebral blood flow in obsessive-compulsive disorder. Psychiatry Res 2003; 124: 113-120. (Pubitemid 38366260)
72. Schwartz JM, Stoessel PW, Baxter Jr LR, Martin KM, Phelps ME. Systematic changes in cerebral glucose metabolic rate after successful behavior modification treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1996; 53: 109-113. (Pubitemid 26049387)
73. Prasko J, Horacek J, Zalesky R, Kopecek M, Novak T, Paskova B et al. The change of regional brain metabolism (18FDG PET) in panic disorder during the treatment with cognitive behavioral therapy or antidepressants. Neuro Endocrinol Letters 2004; 25: 340-348. (Pubitemid 39625042)
74. Furmark T, Tillfors M, Marteinsdottir I, Fischer H, Pissiota A, Langstrom B et al. Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy. Arch Gen Psychiatry 2002; 59: 425-433. (Pubitemid 34477677)
75. Paquette V, Levesque J, Mensour B, Leroux JM, Beaudoin G, Bourgouin P et al. 'Change the mind and you change the brain': effects of cognitive-behavioral therapy on the neural correlates of spider phobia. Neuroimage 2003; 18: 401-409. (Pubitemid 36269149)
76. Straube T, Glauer M, Dilger S, Mentzel HJ, Miltner WH. Effects of cognitive-behavioral therapy on brain activation in specific phobia. Neuroimage 2006; 29: 125-135. (Pubitemid 41828037)
77. Felmingham K, Kemp A, Williams L, Das P, Hughes G, Peduto A et al. Changes in anterior cingulate and amygdala after cognitive behavior therapy of posttraumatic stress disorder. Psychol Sci 2007; 18: 127-129.
78. de Lange FP, Koers A, Kalkman JS, Bleijenberg G, Hagoort P, van der Meer JW et al. Increase in prefrontal cortical volume following cognitive behavioural therapy in patients with chronic fatigue syndrome. Brain 2008; 131(Pt 8): 2172-2180.
79. Uher R, Tansey KE, Malki K, Perlis RH. Biomarkers predicting treatment outcome in depression: what is clinically significant? Pharmacogenomics 2012; 13: 233-240.
80. Kraemer HC, Kupfer DJ. Size of treatment effects and their importance to clinical research and practice. Biol Psychiatry 2006; 59: 990-996. (Pubitemid 43849650)